MTEM Abuzz, TLRY Up 1,240% In 2 Months, ALT Awaits Anthrax Data In Q4

pharma 030717 19sep18

The following are some of today's top gainers in the pharma/biotech sector.

1. Altimmune Inc. (ALT)

Gained 285.48% to close Wednesday's (Sep.19) trading at $16.46.

News: No news


Altimmune is a clinical-stage immunotherapeutics company having three clinical product candidates in its pipeline namely, NasoVAX, a phase II seasonal influenza vaccine candidate, HepTcell, a phase I immunotherapeutic candidate for the potential cure of chronic hepatitis B, SPARVAX-L, a phase II Anthrax vaccine, and NasoShield, a next generation Anthrax vaccine, under phase I study.

Recent events:

-- On September 14, the Company effected a 1 for 30 reverse stock split.
-- On September 4, the Company announced additional positive data from a Phase 2a study of its NasoVAX intranasal influenza vaccine candidate. The results demonstrated a statistically superior mucosal immune response providing a first line of defense against infection; a durable serum immune response at six months compared to over 50% decline with Fluzone, a licensed injectable influenza vaccine, and a continued clean safety profile.

Near-term Catalyst:

Immunogenicity data for two-dose cohort from the phase I study of NasoShield under investigation as a potential vaccine against anthrax is expected to be available in the fourth quarter of this year.

2. Delcath Systems Inc. (DCTH)

Gained 55% to close Wednesday's trading at $8.68.

News: No news


The Company's investigational product - Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) - is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

A global phase III trial of Melphalan/HDS for patients with Hepatic Dominant Ocular Melanoma, dubbed FOCUS, and a registration trial, called ALIGN, for intrahepatic cholangiocarcinoma are underway.

Melphalan/HDS is yet to be approved by the FDA. However, in Europe, it has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT Delivery System, where it has been used at major medical centers to treat a wide range of cancers of the liver.

Recent event:

On August 28, the Company announced that it completed the initial rights offering period and will be extending for an additional 30-day period, until 5:00 PM Eastern time on September 26, 2018.

3. Molecular Templates Inc. (MTEM)

Gained 52.44% to close Wednesday's trading at $6.25.

News: The Company has entered into an agreement with Takeda Pharmaceutical Company Limited for the joint development of CD38-targeted engineered toxin bodies (ETBs) for the treatment of patients with diseases such as multiple myeloma.

Under the terms of the agreement, Takeda will make an upfront payment of $30 million and Molecular Templates is eligible to receive development, regulatory and commercial milestone payments of up to $632.5 million if Molecular Templates exercises its co-development option or $337.5 million if Molecular Templates does not exercise or opts out of its co-development option, and royalties on sales of the commercial product developed through the collaboration.

4. Tilray Inc. (TLRY)

Gained 38.12% to close Wednesday's trading at $214.06. The stock touched an all-time high of $300 in intraday trading, and that represents a gain of nearly 1,240% in 2 months.

News: No news

Recent event:

On Sep.18, the U.S. Drug Enforcement Administration approved the import of a pharmaceutical-grade medical cannabis product produced by Tilray into the United States for a clinical trial focused on Essential Tremor.

Tilray is providing a cannabinoid formulation for the trial in capsule form, which will allow researchers to test an investigational drug product containing two active ingredients extracted from the cannabis plant, cannabidiol (CBD) and tetrahydrocannabinol (THC).

The study is expected to begin in early 2019 with financial support from Tilray and the International Essential Tremor Foundation.

RTTNews has been regularly updating the share price movement of Tilray since its market debut on July 19, 2018.

5. Tyme Technologies Inc. (TYME)

Gained 19.11% to close Wednesday's trading at $2.68.

News: No news

Pipeline and Near-term Catalysts:

The lead product candidate is SM-88, which is currently being evaluated in two ongoing Phase II clinical trials for metastatic pancreatic cancer and prostate cancer.

-- Interim data from Stage 1 of the phase II trial of SM-88 in pancreatic cancer is expected to be presented during a relevant medical meeting in January 2019.
-- Updated data from the phase II trial of SM-88 in prostate cancer is expected in the first quarter of calendar year 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT